Gut Microbiota, the Potential Key to Modulating Humoral Immunogenicity of New Platform COVID-19 Vaccines

Korea University Guro Hospital53 enrolled

Overview

Vaccination is the best way to mitigate the coronavirus disease 2019 (COVID-19) pandemic, but the vaccine immunogenicity may be quite variable from person to person. There is increasing evidence suggesting that the gut microbiome is a major determinant of vaccine immunogenicity. Thus, the investigators investigated the relationship between gut microbiota and humoral immune response after COVID-19 vaccination.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Microbiome Vaccine Covid-19 SARS-CoV-2 Immunogenicity

Interventions

This is observational study

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * People assigned to get either BNT162b2 or ChAdOx1 vaccines * informed concents Exclusion Criteria: * Participants were excluded if they had a history of medication which would affect gut microbiota in the past 1 month, including antibiotics, laxatives, and motility drugs.

Outcomes

Primary Outcomes

Taxonomic biomarkers predicting immune responses

This study aimed to analyze whether fecal microbiota composition before vaccination was associated with immmune response level

Time frame: before the administration of first-dose

Secondary Outcomes

Antibody titres after the first dose vaccination

This study aimed to analyze maximum immune response after first dose vaccination

Time frame: 3weeks from the first-dose administration in BNT162b2 group, 8-12weeks from the first-dose administration in ChAdOx1

Antibody titres after the second dose vaccination

This study aimed to analyze maximum immune response after second dose vaccination

Time frame: 3 weeks from the second dose administration in both BNT162b2 and ChAdOx1 groups